|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schneider G, Siveke JT, Eckel F and Schmid
RM: Pancreatic cancer: Basic and clinical aspects.
Gastroenterology. 128:1606–1625. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gudjonsson B: Pancreatic cancer: Survival,
errors and evidence. Eur J Gastroenterol Hepatol. 21:1379–1382.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wray CJ, Ahmad SA, Matthews JB and Lowy
AM: Surgery for pancreatic cancer: Recent controversies and current
practice. Gastroenterology. 128:1626–1641. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loos M, Kleeff J, Friess H and Büchler MW:
Surgical treatment of pancreatic cancer. Ann NY Acad Sci.
1138:169–180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsumoto R, Matsumoto H, Seki M, Hata M,
Asano Y, Kanegasaki S, Stevens RL and Hirashima M: Human ecalectin,
a variant of human galectin-9, is a novel eosinophil
chemoattractant produced by T lymphocytes. J Biol Chem.
273:16976–16984. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matsushita N, Nishi N, Seki M, Matsumoto
R, Kuwabara I, Liu FT, Hata Y, Nakamura T and Hirashima M:
Requirement of divalent galactoside-binding activity of
ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem.
275:8355–8360. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matsumoto R, Hirashima M, Kita H and
Gleich GJ: Biological activities of ecalectin: A novel
eosinophil-activating factor. J Immunol. 168:1961–1967. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saita N, Goto E, Yamamoto T, Cho I,
Tsumori K, Kohrogi H, Maruo K, Ono T, Takeya M, Kashio Y, et al:
Association of galectin-9 with eosinophil apoptosis. Int Arch
Allergy Immunol. 128:42–50. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Asakura H, Kashio Y, Nakamura K, Seki M,
Dai S, Shirato Y, Abedin MJ, Yoshida N, Nishi N, Imaizumi T, et al:
Selective eosinophil adhesion to fibroblast via IFN-gamma-induced
galectin-9. J Immunol. 169:5912–5918. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dai S, Nakagawa R, Itoh A, Murakami H,
Kashio Y, Abe H, Katoh S, Kontani K, Kihara M, Zhang SL, et al:
Galectin-9 induces maturation of human monocyte-derived dendritic
cells. J Immunol. 175:2974–2981. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nobumoto A, Oomizu S, Arikawa T, Katoh S,
Nagahara K, Miyake M, Nishi N, Takeshita K, Niki T, Yamauchi A and
Hirashima M: Galectin-9 expands unique macrophages exhibiting
plasmacytoid dendritic cell-like phenotypes that activate NK cells
in tumor-bearing mice. Clin Immunol. 130:322–330. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wiersma VR, de Bruyn M, Helfrich W and
Bremer E: Therapeutic potential of Galectin-9 in human disease. Med
Res Rev. 33 Suppl 1:E102–E126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fujihara S, Mori H, Kobara H, Rafiq K,
Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy.
Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kashio Y, Nakamura K, Abedin MJ, Seki M,
Nishi N, Yoshida N, Nakamura T and Hirashima M: Galectin-9 induces
apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol.
170:3631–3636. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu LH, Nakagawa R, Kashio Y, Ito A, Shoji
H, Nishi N, Hirashima M, Yamauchi A and Nakamura T:
Characterization of galectin-9-induced death of Jurkat T cells. J
Biochem. 141:157–172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kobayashi T, Kuroda J, Ashihara E, Oomizu
S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N,
et al: Galectin-9 exhibits anti-myeloma activity through JNK and
p38 MAP kinase pathways. Leukemia. 24:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kuroda J, Yamamoto M, Nagoshi H, Kobayashi
T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima
M and Taniwaki M: Targeting activating transcription factor 3 by
Galectin-9 induces apoptosis and overcomes various types of
treatment resistance in chronic myelogenous leukemia. Mol Cancer
Res. 8:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fujita K, Iwama H, Sakamoto T, Okura R,
Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, et
al: Galectin-9 suppresses the growth of hepatocellular carcinoma
via apoptosis in vitro and in vivo. Int J Oncol. 46:2419–2430.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kobayashi K, Morishita A, Iwama H, Fujita
K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H,
et al: Galectin-9 suppresses cholangiocarcinoma cell proliferation
by inducing apoptosis but not cell cycle arrest. Oncol Rep.
34:1761–1770. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nishi N, Itoh A, Fujiyama A, Yoshida N,
Araya S, Hirashima M, Shoji H and Nakamura T: Development of highly
stable galectins: Truncation of the linker peptide confers
protease-resistance on tandem-repeat type galectins. FEBS Lett.
579:2058–2064. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schutte B, Henfling M, Kölgen W, Bouman M,
Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et
al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp
Cell Res. 297:11–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: Procedure and some applications. Proc Natl
Acad Sci USA. 76:pp. 4350–4354. 1979; View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J Roval Statis Soc. 57:289–300. 1995.
|
|
27
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kageshita T, Kashio Y, Yamauchi A, Seki M,
Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M:
Possible role of galectin-9 in cell aggregation and apoptosis of
human melanoma cell lines and its clinical significance. Int J
Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Irie A, Yamauchi A, Kontani K, Kihara M,
Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H and
Hirashima M: Galectin-9 as a prognostic factor with antimetastatic
potential in breast cancer. Clin Cancer Res. 11:2962–2968. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kramer G, Erdal H, Mertens HJ, Nap M,
Mauermann J, Steiner G, Marberger M, Bivén K, Shoshan MC and Linder
S: Differentiation between cell death modes using measurements of
different soluble forms of extracellular cytokeratin 18. Cancer
Res. 64:1751–1756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Linder S: Cytokeratin markers come of age.
Tumour Biol. 28:189–195. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cummings J, Ranson M, Butt F, Moore D and
Dive C: Qualification of M30 and M65 ELISAs as surrogate biomarkers
of cell death: Long term antigen stability in cancer patient
plasma. Cancer Chemother Pharmacol. 60:921–924. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Scott LC, Evans TR, Cassidy J, Harden S,
Paul J, Ullah R, O'Brien V and Brown R: Cytokeratin 18 in plasma of
patients with gastrointestinal adenocarcinoma as a biomarker of
tumour response. Br J Cancer. 101:410–417. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Morishita A, Gong J and Masaki T:
Targeting receptor tyrosine kinases in gastric cancer. World J
Gastroenterol. 20:4536–4545. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cohenuram M and Saif MW: Epidermal growth
factor receptor inhibition strategies in pancreatic cancer: Past,
present and the future. JOP. 8:4–15. 2007.PubMed/NCBI
|
|
36
|
Ueda S, Ogata S, Tsuda H, Kawarabayashi N,
Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K and Mochizuki
H: The correlation between cytoplasmic overexpression of epidermal
growth factor receptor and tumor aggressiveness: Poor prognosis in
patients with pancreatic ductal adenocarcinoma. Pancreas. 29:e1–e8.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Morishita A and Masaki T: miRNA in
hepatocellular carcinoma. Hepatol Res. 45:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Marin-Muller C, Li D, Bharadwaj U, Li M,
Chen C, Hodges SE, Fisher WE, Mo Q, Hung MC and Yao Q: A
tumorigenic factor Interactome connected through tumor suppressor
MicroRNA-198 in human pancreatic cancer. Clin Cancer Res.
19:5901–5913. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner
MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen
TD: Expression profiling identifies microRNA signature in
pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jiang J, Gusev Y, Aderca I, Mettler TA,
Nagorney DM, Brackett DJ, Roberts LR and Schmittgen TD: Association
of MicroRNA expression in hepatocellular carcinomas with hepatitis
infection, cirrhosis, and patient survival. Clin Cancer Res.
14:419–427. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shi W, Gerster K, Alajez NM, Tsang J,
Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, et al:
MicroRNA-301 mediates proliferation and invasion in human breast
cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu Z and Li Y, Takwi A, Li B, Zhang J,
Conklin DJ, Young KH, Martin R and Li Y: miR-301a as an NF-κB
activator in pancreatic cancer cells. EMBO J. 30:57–67. 2011.
View Article : Google Scholar : PubMed/NCBI
|
